Looking Closely at the Growth Curve for Nurix Therapeutics Inc. (NRIX) – News Heater
Home  »  Business   »  Looking Closely at the Growth Curve for Nurix Ther...

Looking Closely at the Growth Curve for Nurix Therapeutics Inc. (NRIX)

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Nurix Therapeutics Inc. (NASDAQ:NRIX) went up by 4.62% from its latest closing price compared to the recent 1-year high of $52.38. The company’s stock price has collected 32.58% of gains in the last five trading sessions. Press Release reported on 07/13/21 that Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

>> 7 Top Picks for the Post-Pandemic Economy <<

Is It Worth Investing in Nurix Therapeutics Inc. (NASDAQ :NRIX) Right Now?

Opinions of the stock are interesting as 6 analysts out of 7 who provided ratings for Nurix Therapeutics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $48.71. NRIX currently public float of 43.30M and currently shorts hold a 10.98% ratio of that float. Today, the average trading volume of NRIX was 383.36K shares.

NRIX’s Market Performance

NRIX stocks went up by 32.58% for the week, with a monthly jump of 0.57% and a quarterly performance of -6.92%. The volatility ratio for the week stands at 8.83% while the volatility levels for the past 30 days are set at 6.73% for Nurix Therapeutics Inc.. The simple moving average for the period of the last 20 days is 14.65% for NRIX stocks with a simple moving average of -8.36% for the last 200 days.

Analysts’ Opinion of NRIX

Many brokerage firms have already submitted their reports for NRIX stocks, with Robert W. Baird repeating the rating for NRIX by listing it as a “Outperform.” The predicted price for NRIX in the upcoming period, according to Robert W. Baird is $46 based on the research report published on June 04th of the current year 2021.

Piper Sandler, on the other hand, stated in their research note that they expect to see NRIX reach a price target of $60. The rating they have provided for NRIX stocks is “Overweight” according to the report published on April 30th, 2021.

RBC Capital Mkts gave a rating of “Outperform” to NRIX, setting the target price at $42 in the report published on April 30th of the current year.

NRIX Trading at 10.63% from the 50-Day Moving Average

After a stumble in the market that brought NRIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.52% of loss for the given period.

Volatility was left at 6.73%, however, over the last 30 days, the volatility rate increased by 8.83%, as shares surge +4.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.06% upper at present.

During the last 5 trading sessions, NRIX rose by +32.58%, which changed the moving average for the period of 200-days by +13.77% in comparison to the 20-day moving average, which settled at $26.33. In addition, Nurix Therapeutics Inc. saw -8.42% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at NRIX starting from Ring Christine, who sale 1,200 shares at the price of $27.00 back on Jul 20. After this action, Ring Christine now owns 805 shares of Nurix Therapeutics Inc., valued at $32,400 using the latest closing price.

Beaurang Pierre, the Chief Business Officer of Nurix Therapeutics Inc., sale 7,500 shares at $23.92 during a trade that took place back on Jul 12, which means that Beaurang Pierre is holding 4,330 shares at $179,419 based on the most recent closing price.

Stock Fundamentals for NRIX

Current profitability levels for the company are sitting at:

  • -364.66 for the present operating margin

The net margin for Nurix Therapeutics Inc. stands at -242.66. The total capital return value is set at -46.29, while invested capital returns managed to touch -30.80. Equity return is now at value -28.10, with -20.70 for asset returns.

>> 7 Top Picks for the Post-Pandemic Economy <<

The receivables turnover for the company is 3.14 and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.70.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Is Unum Group (UNM) a Keeper?

Unum Group (NYSE:UNM) went down by -0.29% from its latest closing price compared to the recent 1-year high of $31.98. The company’s stock price has

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam